Potential value and mechanism of Rosa roxburghii tratt juice on pro-inflammatory responses in peripheral blood of patients with arsenic poisoning

Abstract

Increasing evidence supports the role of arsenic in dysregulated immune and inflammation responses, while, safe and effective treatments have not been fully examined. Rosa roxburghii Tratt (RRT), a traditional Chinese edible fruit with potential immunoregulatory activities, was considered as a dietary supplement to explore its protective effects and possible mechanism in arsenic-induced dysregulated inflammation responses. We enrolled 209 arsenicosis patients and 41 controls to obtain baseline data, including the degree of arsenic poisoning prior to the RRT juice (RRTJ) intervention. Then, based on criteria of inclusion and exclusion and the principle of voluntary participation, 106 arsenicosis patients who volunteered to receive treatment were divided into RRTJ (n = 53) and placebo (n = 53) groups randomly. After three months follow-up, 89 subjects (46 and 43 of the RRTJ and placebo groups, respectively) completed the study and were examined for the effects and possible mechanisms of RRTJ on the Th17 cells-related pro-inflammatory responses in peripheral blood mononuclear cells (PBMCs). The PBMCs had higher levels of Th17 and Th17-related inflammatory cytokines IL-17, IL-6, and RORγt. Furthermore, the gene expressions of STAT3 and SOCS3 in PBMCs increased and decreased, respectively. Conversely, RRTJ decreased the number of Th17 cells, secretion of IL-17, IL-6, RORγt, and relative mRNA levels of STAT3, and increased the transcript levels of SOCS3. This study provides limited evidence that possible immunomodulatory effects of RRTJ on the critical regulators, IL-6 and STAT3, of the Th17 cells in arsenicosis patients, which indicated that IL-6/STAT3 pathway might appear as a potential therapeutic target in arsenicosis.

Keywords

Rosa roxburghii tratt juice IL-6/STAT3 arsenic inflammation response

Introduction

Exposure to arsenic is a major environmental and public health challenge for hundreds of millions of people worldwide.¹ Epidemiological studies have proved that long-term exposure to arsenic via contaminated drinking water, diet, or air can cause various adverse health effects in humans (respiratory, digestive, urinary, cardiovascular, and immune systems).^2–6 Recent studies found that arsenic exposure can cause inflammatory damage to the body’s immune system,^7–9 and T helper 17 (Th17) cells, a unique CD4⁺ T-cell subset characterized by the production of interleukin-17 (IL-17).^10,11 IL-17 can effectively mediate neutrophil mobilization and pro-inflammatory responses that ultimately lead to inflammatory cell infiltration and tissue damage.¹² Retinoid-related orphan receptor-γt (RORγt) is the most specific transcription factor promoting Th17 cells, the gene expression profiles of Th17 cells indicate a high expression of RORc gene, which encodes RORγt in Th17 cells. Retroviral vector mediated transduction of RORγt into naive T cells promoted the development of Th17 cells, suggesting a clear association between RORγt and Th17 cells.¹³ Patients with arsenic poisoning [0.23(0.10–0.57) μg/g hair] have higher levels of Th17 cells, protein level of IL-17A, and transcript level of RORγt,¹⁴ however, the exact mechanism remains unclear. Current studies tend to assume that inflammation leads to injury through the interleukin-6 (IL-6)/signal transducer and activator of the transcription 3 (STAT3) signaling pathway, which is considered a major target for the treatment of inflammatory diseases.^15–17 The suppressor of cytokine signaling 3 (SOCS3) is an inhibitory factor of the IL-6/STAT3 signaling pathway. IL-6 can induce STAT3 phosphorylation (p-STAT3), and p-STAT3 activates SOCS3, which in turn inhibits the activation of STAT3, thus negatively regulating the IL-6/STAT3 signal.¹⁸ Nishihara M et al. reported a novel role of the IL-6/STAT3 signaling pathway in the Th17 response, where IL-6 acts directly to promote the development of Th17 by activating the T cell gp130-STAT3 pathway.¹⁹ In addition, Li Y et al. revealed that the inhibition of IL-6/STAT3 pathway by triptolide could significantly reduce the production of IL-17.²⁰ To date, the underlying mechanisms of IL-6/STAT3 signaling in the Th17 response and IL-17 production on arsenicosis patients have not been elaborated. Study found that SOCS3 has a significant role in constraining the generation of Th17 cells,²¹ a study demonstrated that an enhanced stimulation of macrophages and promotion of Th17 cell differentiation by down-regulation of the SOCS3-mediated IL-6/STAT3 pathway feedback inhibition.²² Those studies suggest that SOCS3 might inhibit the Th17 cells-related pro-inflammatory responses via IL-6/STAT3 signaling. However, whether IL-6/STAT3 signaling is involved in Th17-induced pro-inflammatory responses in patients with arsenic poisoning remains unknown.

At present, there is still no effective treatment for arseniasis in biological systems, which should be of concern to the research of arsenic-induced diseases and their effective and safe treatment. Plants are used to treat diseases since ancient times.²³ Modulation of inflammation with the use of edible and medicinal plants poses an alternative to conventional therapeutic strategies for numerous ailments, including arseniasis.²⁴ RRT, the fruit of R. roxburghii Tratt.f. normalis Rehd. Et Wils., is a promising wild fruit crop growing in Southwest China and particularly the Guizhou Province,²⁵ and it is recognized for its nutritional and potential immunoregulatory activities; it has long been considered as a healthy edible fruit, and it is related to improved function of the immune system, reduced blood lipid and glucose levels, and improved antioxidant capacity.^26–31 RRTJ retains the original nutrients and bioactive properties of RRT and can be used as a dietary supplement.³² Some studies have found that RRTJ could effectively improve the immune function of rats-exposed to arsenic (RRTJ was used in 10 mL/kg for 45 d after cessation of arsenic exposure) and arseniasis patients (patients received 120 mL/d RRTJ orally for one month),^33,34 however, the mechanism has not been extensively investigated.

Although Th17 cells play a pivotal role in immune diseases, there is no data on RRTJ as a protective factor for Th17-related pro-inflammatory responses. Thus, we recruited a population exposed to arsenic via coal-burning to observe whether arsenic could increase the number of Th17 cells via activating IL-6/STAT3 signaling and explored the protective effects and possible mechanism of RRTJ in arsenic-induced pro-inflammatory responses. We determined the numbers of Th17 cells in PBMCs, the Th17-related levels of transcription factors and cytokines (protein levels of IL-17, IL-6, and the mRNA levels of RORγt, STAT3, and SOCS3). In addition, we examined the regulatory effects of RRTJ on the Th17 response. In present study, we aimed to explore the effects of RRTJ in the modulation of Th17 response in arsenic-exposed individuals.

Methods

Selection of population

The subjects were selected from Yuzhang Town, a coal-burning region in China that suffers from arsenic poisoning, and is located in Xingren County of Qianxinan Prefecture, Guizhou Province, Southwest China. To obtain baseline data, including the degree of arsenic poisoning in the population prior to the RRTJ intervention, 209 arsenicosis patients were enrolled and classified by trained biomedical personnel into mild (palmo plantar with skin keratosis of grade I or trunk with skin pigmentation of grade I and depigmentation of grade I simultaneously), intermediate (palmo plantar with skin keratosis or trunk with skin pigmentation of grade II or depigmentation of grade II), and severe (palmo plantar with skin keratosis or trunk with skin pigmentation of grade III or depigmentation of grade III)groups based on the different degree of arsenicosis skin damage symptoms using the Diagnosis of Endemic Arsenicosis WS/T 211-2015.³⁵ In addition, 41 participants from an arsenic-free area who shared a similar lifestyle, eating habits, nutritional status, and economic status were recruited as controls. The inclusion criteria included (1) participants have a history of arsenic exposure in Yuzhang Town, a typical coal-burning arsenic poisoning region in China; (2) aged 18–65 years; and (3) with hyperkeratosis, hyperpigmentation or depigmentation, and skin ulceration. Also, the exclusion criteria were defined as the following: (1) history of occupational arsenic poisoning; (2) long-term suffering from immunodeficiency or autoimmune-related diseases; (3) a recent history of infection, consuming drugs or intaking seafood that can affect immune function or the arsenic metabolism; (4) exposure to X-rays or other radioactive materials for a long time; and (5) unwillingness to join the study. Study materials and procedures were reviewed and approved by the Ethical Committee of Guizhou Medical University for international health research (No. 201403001), and written informed consent was obtained from all individuals.

Study design

The present study was designed as a double-blind, randomized, placebo-controlled trial to assess the potential value of RRTJ on arsenic-induced inflammatory processes. We enrolled 209 arsenicosis patients and 41 controls to obtain baseline data, including the degree of arsenic poisoning prior to the RRTJ intervention. Then, according to the criteria of inclusion and exclusion and the principle of voluntary participation, 106 arsenicosis patients were divided into different block groups according to age (an interval every 5 years) and gender; the same block group was distributed to the RRTJ (53) and placebo (53) groups randomly and were subjected to three months of oral administration of RRTJ (20 mL per day according to the recommended dosage in the health food instructions; RRTJ was purchased from Sinopharm Group Guizhou Healthcare Industry Development Co., Ltd; the health food permission number of National Health Commission of the People’s Republic of China is [2002]0004) or placebo tablets (20 mL per day, no RRTJ active ingredients, color and taste are consistent with those of RRTJ). Both participants and investigators were blind to the treatment conditions until the study was finished. At baseline and at the final follow-up, physical examinations were performed by medical professionals who worked in the former 44th Hospital of the Chinese People’s Liberation Army. The grouping and study-flow diagram are shown in Figure 1.

Figure 1.

Grouping and study-flow diagram. Grouping proceeded according to the Standard of Diagnosis for Endemic Arsenism (WS/T 211-2015, Ministry of Health of the People’s Republic of China), 41 normal controls and 209 arsenicosis patients were recruited to study the effects and possible mechanisms of RRTJ on the Th17 cells-related pro-inflammatory responses in PBMCs. According to the criteria of inclusion and exclusion and the principle of voluntary participation, arsenicosis patients were divided into a placebo (n = 53) and RRTJ (n = 53) groups randomly. After three months, 17 arsenicosis patients did not fully participate in the intervention, while the remaining subjects in the RRTJ (n = 46) and placebo (n = 43) groups were examined for the effects and possible mechanisms of RRTJ on the Th17 cells-related pro-inflammatory responses in PBMCs.

Sample collection

The hair of the subjects was collected within 3 cm of the hair root and stored in plastic zipper bags. Fasting venous blood samples were collected into tubes containing sodium heparin and non-anticoagulant tubes at the baseline and after RRTJ intervention. Serum was obtained after centrifugation at 400 × g for 20 min, and the blood samples were stored at −80°C until analysis. The PBMCs were isolated from heparinized blood by Ficoll density gradients³⁶ for flow cytometric analysis and extraction of total RNA.

Determination of arsenic levels in hair

The concentration of arsenic in the hair samples was tested as previously described.³⁷ Briefly, the hair samples were washed with deionized water, soaked in acetone, dehydrated with ether, dried in an oven at 60 °C, and cut into pieces. Before the determination, hair samples were digested with 6 mL of concentrated nitric acid (HNO₃) using a microwave digestion instrument (Anton Paar, Multiwave GO, Sweden) for 1 h. Inductively coupled plasma mass spectrometry (Thermo Fisher, XSeries 2, USA) was used to analyze the total arsenic content in the hair samples.³⁸

Cell isolation and flow cytometric analysis

Cell isolation and flow cytometric analysis were performed as described in the literature.¹⁴ Briefly, PBMCs were isolated from the fresh heparinized blood by Ficoll-Hypaque (Tian Jin Hao Yang Biological Manufacture Co., Tianjin, China) gradient centrifugation at 800 × g for 20 min, and distributed in 24-well plates at a density of 2 × 10⁶ cells/mL coated with 4 μL Leukocyte Activation Cocktail with BD Golgi Plug™ (BD Biosciences, San Jose, CA, USA) at 37 °C with 5% CO₂ for 5 h. Then, the cells were suspended in a FACS solution and incubated with cell surface antibodies FITC-labelled antihuman CD4 (BD Biosciences, USA) at 4 °C for 30 min in the dark. Fixation & permeabilization solution (BD Biosciences, USA) was used to permeabilize the membrane of the cell cytoplasm and nucleus at 4°C for 50 min for the intracellular staining, and the cells were incubated with cell intracellular and nuclear antibodies PE-cyanine7-labelled antihuman IL-17A (BD Biosciences, USA) at 4 °C for 40–50 min in the dark. The isotype controls were treated with the same procedures and then washed with a FACS solution. A stopping gate of 10,000 CD4⁺ events was set and the stained cells were analyzed with a FACS Calibur^TM Flow Cytometer (BD Biosciences, San Jose, CA, USA). Data analysis was performed using the Cell Quest Pro software (BD Biosciences).

Measurement of serum cytokines via ELISA

The levels of IL-17, and IL-6 in the serum were measured following the manufacturer’s instructions. The Human IL-17A Platinum ELISA Kit (catalog number: BMS 2017) was purchased from eBioscience (San Diego, CA) and BD OptEIA™ Human IL-6 ELISA Kit II (catalog number: 550799) was purchased from BD Biosciences (BD Biosciences, USA). The concentrations were calculated from the absorbance, which was recorded at 450 nm in a microplate reader (Thermo Fisher). All samples were tested in parallel.

Real-time PCR analysis

The RNA was isolated as previously described.¹³ Briefly, total RNA was isolated from PBMCs by using Trizol reagent (Thermo Fisher/Invitrogen, USA). 1 μg RNA was then converted to cDNA with Revert Aid TM first-strand cDNA synthesis Kits (Thermo Fisher, USA) according to manufacturer’s instructions. Real-time polymerase chain reaction (RT-PCR) was performed in 10 μL, with the final volume containing 0.5 μL of each primer (Primer sequences of RORγt, STAT3, and SOCS3 for RT-PCR are shown in Table 1), 1 μL of cDNA, 3 μL of RNase/DNase-free water, and 5 μL SYBR Green Master Mix (TaKaRa, Japan). The PCR amplification conditions consisted of initial denaturation at 95 °C for 3 min, followed by 39 cycles of denaturation for at 95 °C for 10 s, annealing at 60 °C for 30 s and extension at 72 °C for 30 s. GAPDH was used as a housekeeping gene. The fold changes in the relative expression of each gene were calculated based on the 2^-△△Ct method.³⁹

Table 1.

Primer sequences for real-time PCR.

Genes	Primers	Size (bp)
RORγt	Forward primer: 5’-CTGCTGAGAAGGACAGGGAG-3’	202
	Reverse primer: 5’-AGTTCTGCTGACGGGTGC-3’
STAT3	Forward primer:5’-ACCAACAATCCCAAGAATGTAAACT-3’	188
	Reverse primer: 5’-CATGTGATCTGACACCCTGAATAAT-3’
SOCS3	Forward primer: 5’-CACAAGTGGATTCTCCTTGAATTC-3’	132
	Reverse primer: 5’-ATCAAAGAGCAAACAAGTTCCGT-3’
GAPDH	Forward primer: 5’-GGACCTGACCTGCCGTCTAG-3’	100
	Reverse primer: 5’-GTAGCCCAGGATGCCCTTGA-3’

Statistical analysis

SPSS 22.0 software (SPSS, Inc., Chicago, IL, USA) was used for statistical analysis. The graphs were plotted using the GraphPad Prism software, version 8.3 (GraphPad Software). Prescriptive data are presented as mean ± standard deviations (SD). A chi-squared test, paired t-test and one-way analysis of variance (ANOVA) were used for comparison between the before and after variables and within groups, respectively. The Kruskal-Wallis H and Wilcoxon Signed-rank tests were used when data were presented as median (interquartile range). Spearman’s rank correlation coefficients analysis was applied. Differences were considered statistically significant at p < 0.05.

Results

Demographic data of the study population

In present study, we enrolled 209 arsenicosis patients (63, 73, and 73 cases in the mild, intermediate, and severe groups, respectively) and 41 controls. Then, according to the principle of voluntary participation, 106 arsenicosis patients were randomly assigned to the RRTJ (53) or placebo (53) treatment groups. During the three months of follow-up, 17arsenicosis patients did not fully participate in the intervention; 46 cases in the RRTJ group (16, 16, and 14 cases in mild, intermediate, and severe groups) and 43 cases in the placebo group (13, 15, and 15 cases in mild, intermediate, and severe groups) completed the intervention and were analyzed. The characteristics of the study subjects are summarized in Table 2. The gender and age of the arsenicosis and control groups were different (χ² = 33.106, F = 8.190. p < 0.001). Table 2 shows that the arsenicosis patients had higher hair arsenic levels than those in the control group (H = 53.008, p< 0.001). The level of hair arsenic tended to increase with the degree of arsenicosis. As presented in Supplementary Table 3, there were no significant differences in terms of gender and age between the RRTJ group and the placebo group (χ² = 0.204, t = 0.320, p > 0.05). It is indicated that the age, gender and severity of arsenic poisoning in the two groups are roughly matched.

Table 2.

Characteristics of the study population in baseline.

Variable	Controls	Arsenicosis grades			Statistical values	p value
Variable	Controls	Mild	Intermediate	Severe	Statistical values	p value
Age	45.76 ± 7.83	51.05 ± 8.41	52.30 ± 7.66	52.55 ± 6.69	8.190	<0.001^a
Gender
Male	12	27	35	58	33.106	<0.001^b
Female	29	36	38	15
Hair arsenic (μg/g)	0.12(0.08–0.18)	0.20(0.15–0.30)^*	0.25(0.18–0.36)^*	0.26(0.21–0.41)^*#	53.008	<0.001^c

Arsenic induced pro-inflammation responses in peripheral blood of patients with arsenic poisoning

Arsenic disrupted the quantity of Th17 cells in PBMCs

The percentages of Th17 cells in the PBMCs were detected based on their specific surface markers. There were differences in terms of Th17/PBMCs and Th17/CD4⁺T among control and arsenicosis groups (F = 3.973, 33.902, p = 0.009, p < 0.001, respectively). Compared with control group (0.28 ± 0.16 % and 1.03 ± 0.44 %), the frequencies of Th17 cells/PBMCs and Th17 cells/CD4⁺T cells increased by 0.16 % and 0.17 %, and by 1.06 %, and 1.12 % (p < 0.05) in the PBMCs of intermediate and severe arsenicosis patients, respectively. There were no significant differences in terms of Th17/PBMCs between control and mild group (p > 0.05) (Figure 2). These results suggested that sustained arsenic exposure promoted differentiation and significantly disturbed the expression of Th17 cells.

Figure 2.

Higher percentages of Th17 cells in peripheral blood caused by arsenic. To evaluate the effect of arsenic exposure on the immune response, we assessed the frequencies of Th17 cells in the PBMCs of arsenicosis patients using a FACS Calibur^TM Flow Cytometer. Arsenic increases the level of Th17 in both PBMCs and CD4⁺ T cells, and triggers a response of Th17-related immunological dysregulation. PBMCs were obtained from control subjects and arsenicosis patients. (a, b and c) Representative flow cytometry (FCM) pictures of CD4⁺IL-17A⁺ Th17 cells in the PBMCs and in CD4⁺T cells of the subjects, FITC-labelled antihuman CD4, PE-cyanine7-labelled antihuman IL17A. A stopping gate of 10,000 CD4⁺ events was set and the stained cells were analyzed with a FACSCalibur^TM Flow Cytometer. (d and e) The percentages of Th17 cells in PBMCs and in CD4⁺T cells were measured via FCM according to their specific surface markers. The Th17 cells were defined as CD4⁺IL-17⁺T cells, FITC-labelled antihuman CD4, PE-cyanine7-labelled antihuman IL17A. Data analysis was performed using the Cell Quest Pro software (BD Biosciences). Results are given as mean ± SD. ^*p< 0.05 compared with that in the control; ^#p<0.05 compared with that in the mild group.

Arsenic increases the levels of IL-17 and IL-6 in serum

To determine the inflammatory response in the PBMCs, the levels of pro-inflammatory related cytokines IL-17 and IL-6 in the serum were determined using ELISA kits according to the manufacturer’s instructions. As presented in Figure 3, there were differences in the levels IL-17 and IL-6 among control and arsenicosis groups (F = 27.946 and 43.972, respectively; p < 0.001). Both the levels IL-17 and IL-6 in the arsenicosis groups [mild(11.86 ± 1.92 pg/mL and 9.95 ± 1.55 pg/mL), intermediate (12.87 ± 1.70 pg/mL and 10.45 ± 1.38 pg/mL), and severe (13.50 ± 1.72 pg/mL and 11.34 ± 1.77 pg/mL), respectively] were increased by 1.88 pg/mL and 2.62 pg/mL, 2.89 pg/mL and 3.12 pg/mL, 3.52 pg/mL and 4.01 pg/mL than in the control group (9.98 ± 1.66 pg/mL and 7.33 ± 1.52 pg/mL, p < 0.05). Furthermore, the levels of IL-6 and IL-17 in the severe group was higher than that in the mild group and were increased by 1.39 pg/mL and 1.64 pg/mL, respectively (p < 0.05). The level of IL-17 in the intermediate group was higher than in the mild group and was increased by 1.01 pg/mL (p < 0.05). These results revealed that higher levels of IL-17 and IL-6 in the serum might be involved in inflammatory responses in arsenicosis patients.

Figure 3.

Arsenic exposure leads to higher levels of IL-6 and IL-17 in serum. Arsenic exposure can increase the secretion of serum IL-6 and IL-17, which might be involved in inflammatory responses in arsenicosis patients. The levels of IL-6 (a) and IL-17 (b) in serum were measured using ELISA. Results are given as mean ± SD. ^*p < 0.05 compared with that in the control group; ^#p< 0.05 compared with that in the mild group.

Arsenic exposure might activate the IL-6/STAT3 pathway in PBMCs

To explore the possible mechanisms underlying Th17-related pro-inflammatory responses in the PBMCs of arsenicosis patients, we measured the mRNA expression of RORγt, STAT3, and SOCS3 in PBMCs. As shown in Figure 4, there were differences in the levels of RORγt, STAT3 and SOCS3 among control and arsenicosis groups (F = 4.548, 20.301, and 12.112, respectively; P all<0.05). RT-PCR showed higher levels of RORγt and STAT3 but lower levels of SOCS3 transcripts in PBMCs in intermediate [2.31(0.42∼3.38), 2.41(1.61∼4.11) and 0.57(0.14∼0.94) fold changes, respectively] and severe [2.61(1.46∼3.81), 3.15(2.17∼4.76) and 0.50(0.18∼0.79) fold changes, respectively] group than that in the control group [1.08(0.62∼1.38), 1.00(0.76∼1.50) and 0.88 (0.49∼1.40) fold changes, respectively, p < 0.05]. There were no significant differences of the level of RORγt transcripts between mild group [1.85(0.02∼2.76) fold changes] and control group (p > 0.05). Combined with the abnormal inflammatory cytokines IL-6 and IL-17, these data suggested that arsenic exposure might increase the levels of IL-6 and STAT3, which might be involved in Th17-related pro-inflammatory responses in the PBMCs of arsenicosis patients. The current study revealed that the levels of Th17 cells, as well as the concentration of Th17 cell-related cytokines IL-17 and IL-6 in the PBMCs, increased significantly. To further explore the role of the IL-6/STAT3 signaling-related transcription factors in Th17-induced pro-inflammatory responses, we used Spearman’s correlation analysis to assay the hair arsenic, IL-6/STAT3 signaling-related transcription factors and pro-inflammatory changes. As shown in Table 3, we evaluated the correlations between hair arsenic and Th17/PBMCs (%), Th17/CD4⁺T (%), IL-17 and IL-6 in arsenicosis patients. The hair arsenic positively correlated with that Th17/PBMCs (%), Th17/CD4⁺T (%) as well as pro-inflammatory related cytokines IL-17 and IL-6 (r_s = 0.225, 0.483, 0.439, and 0.450, respectively; P all<0.05). Moreover, We examined the correlations between STAT3/SOCS3 and Th17/PBMCs (%), Th17/CD4⁺T (%), IL-17 and IL-6 in arsenicosis patients, the gene level of STAT3 correlated positively (r_s = 0.337, 0.305, and 0.370, respectively; P all<0.05) but the transcript level of SOCS3 negatively with Th17/CD4⁺T (%), IL-17 and IL-6 (r_s = −0.274, −0.253, and −0.220, respectively; P all < 0.05); this indicated that IL-6/STAT3 signaling may be associated with Th17-related pro-inflammatory responses in the PBMCs of arsenicosis patients.

Figure 4.

Arsenic exposure increases the mRNA levels of RORγt and STAT3, but decreases those of SOCS3 in PBMCs. To explore the possible mechanisms underlying Th17-related pro-inflammatory responses in the PBMCs of arsenicosis patients, we measured the mRNA expressions of RORγt, STAT3, and SOCS3 in the PBMCs. RT-qPCR showed higher levels of RORγt and STAT3 but lower levels of SOCS3 transcripts in PBMCs based on the degree of arsenicosis. The mRNA levels of RORγt (a), STAT3 (b) and SOCS3 (c) were determined via qRT-PCR. Results are presented as median (interquartile range); M: median; P25, P75: interquartile range. ^*p < 0.05 compared with that in the control group; ^#p< 0.05 compared with that in the mild group. A one-way ANOVA test was performed, with the F-value as the statistical value.

Table 3.

Relationship betweenTh17-induced pro-inflammatory responses and IL-6/STAT3 signaling in arsenicosis patients.

	Hair arsenic		STAT3		SOCS3
	r _s	P	r _s	P	r _s	P
Th17/PBMCs(%)	0.225	<0.001	0.211	0.001	−0.161	0.012
Th17/CD4⁺T(%)	0.483	<0.001	0.337	<0.001	−0.274	<0.001
IL-17 (pg/mL)	0.439	<0.001	0.305	<0.001	−0.253	<0.001
IL-6 (pg/mL)	0.450	<0.001	0.370	<0.001	−0.220	<0.001

RRTJ ameliorated dysregulated immune and inflammation responses

RRTJ decreased the arsenic concentration in hair of arsenicosis patients

The arsenic levels in the hair of arsenicosis patients decreased by 0.03 μg/g after treatment with RRTJ (T = −2.372, p = 0.018), which suggested that RRTJ may have an important function in the removal of arsenic (Table 4).

Table 4.

Hair arsenic in arsenicosis patients treated with RRTJ or placebo, M (P25∼P75).

Groups	n	Hair arsenic (μg/g)		T value	p value
Groups	n	Before	After	T value	p value
RRTJ	46	0.24(0.15∼0.35)	0.21(0.10∼0.38)^**	−2.372	0.018
Placebo	43	0.28(0.20∼0.41)	0.29(0.18∼0.54)	−0.610	0.542

RRTJ treatment restored the quantity of Th17 cells

To investigate the possible effects of RRTJ on the number of Th17 cells, PBMCs were isolated, and flow cytometric analysis was performed to determine the quantity of the Th17 cells. The number of both Th17/PBMCs and Th17/CD4⁺T cells decreased after treatment with RRTJ (0.32 ± 0.17 % and 1.53 ± 0.36 %) compared with that before (0.42 ± 0.20 % and 2.04 ± 0.62 %, t = 2.718, and 5.097, respectively, p < 0.05). There were no significant differences in terms of Th17/PBMCs and Th17/CD4⁺T before (0.40 ± 0.22 % and 2.04 ± 0.56 %, respectively) and after the placebo treatment (0.41 ± 0.19 % and 1.97 ± 0.42 %, t = −0.302, and 1.037; p = 0.975, and 0.306, respectively). The results suggested that RRTJ could lighten the pro-inflammatory responses caused by imbalanced differentiation of Th17 cells in the PBMCs of arsenicosis patients (Figure 5).

Figure 5.

Effect of RRTJ on the number of Th17 cells in peripheral blood. PBMCs were obtained as described in the Methods section. The arsenicosis patients were treated with RRTJ (n = 46) or placebo (n = 43) for three months. (a, b and c) Representative flow cytometry (FCM) pictures of CD4⁺IL-17A⁺ Th17 cells in the PBMCs and in CD4⁺T cellsof the subjects, FITC-labelled antihuman CD4, PE-cyanine7-labelled antihuman IL17A. A stopping gate of 10,000 CD4⁺ events was set and the stained cells were analyzed with a FACSCalibur^TM Flow Cytometer. (d and e) The percentage of Th17 cells in PBMCs and in CD4⁺T cells were measured via FCM according to their specific surface markersin both groups. The Th17 cells were defined as CD4⁺IL-17⁺T cells, FITC-labelled antihuman CD4, PE-cyanine7-labelled antihuman IL17A. Data analysis was performed using the Cell Quest Pro software (BD Biosciences). Results are presented as mean ±SD. A paired t-test was performed, with the t-value as the statistical value. ^**p<0.05 compared with that before treatment.

RRTJ decreases the levels of IL-17 and IL-6 in serum

To observe the role of RRTJ on the arsenic-induced pro-inflammatory response, we further focused on the concentration levels of the signature cytokines IL-17 and IL-6 of Th17 cells in the serum of arsenicosis patients who were treated with RRTJ or placebo. As shown in Figure 6, the levels of IL-17 and IL-6 decreased after treatment with RRTJ (10.63 ± 1.98 pg/mL and 8.86 ± 1.81 pg/mL) compared with that before (12.68 ± 1.80 pg/mL and 10.54 ± 1.75 pg/mL), their levels decreased by 2.05 pg/mL, and 1.68 pg/mL, respectively (t = 7.257, and 4.867, p < 0.001). However, there were no significant differences in the serum IL-17 and IL-6 before (12.68 ± 1.95 pg/mL and 11.03 ± 1.76 pg/mL, respectively) and after the placebotreatment (12.57 ± 2.08 pg/mL and 10.35 ± 1.85 pg/mL, respectively, t = 0.272, and 1.853; p > 0.05). These data indicated that RRTJ intervention suppressed the pro-inflammatory response by decreasing the secretion of pro-inflammatory cytokines corresponding to Th17 cells in the serum.

Figure 6.

RRTJ can decrease the expression of IL-6 and IL-17 in the serum of arsenicosis patients. RRTJ intervention can downregulate the expression level of IL-6 and IL-17 in the serum of arsenicosis patients, modulating the response of arsenic-induced immunological dysfunction. The serum levels of IL-6 (a) and IL-17 (b) in two groups were measured using ELISA. Results are given as mean ± SD. ^**p<0.05 compared with that before treatment. A paired t-test was performed, and the statistical value was the t-value.

RRTJ-mediated protective effects may be involved in IL-6/STAT3 signaling

To explore whether the IL-6/STAT3 signaling was involved in the protective effects of RRTJ, we performed RT-PCR to detect the mRNA levels of RORγt, STAT3, and SOCS3 in arsenicosis patients who were treated with RRTJ or placebo. As shown in Figure 7, compared to self control before intervention, the expression of RORγt mRNA decreased by 1.42-fold changes after RRTJ-treatment compared to that before the RRTJ-treatment (T = −3.203, p = 0.001). The expression pattern of STAT3 mRNA was similar, the expression level of STAT3 mRNA decreased by 0.87-fold changes after treatment with RRTJ (T = −2.623, p = 0.009). Conversely, the expression of SOCS3 mRNA increased by 0.27-fold changes in the RRTJ-treated group compared to that before the RRTJ-treatment (T = −2.373, p = 0.018). Furthermore, there were no significant differences in the mRNA expression of RORγt, STAT3 and SOCS3 in the PBMCs of the groups before and after the placebo treatment (T = −0.000, −0.305, and 0.000; p = 1.000, 0.760, and 1.000). These findings suggested that, in the PBMCs of arsenicosis patients, RRTJ could attenuate the Th17-related pro-inflammatory response, which could be associated with lower expression of RORγt and STAT3 but higher expression of SOCS3. The results indicated that RRTJ-mediated protective effects may be involved in the IL-6/STAT3 signaling.

Figure 7.

Changes in mRNA levels of RORγt, STAT3, and SOCS3 in arsenicosis patients treated with RRTJ or placebo. The mRNA levels of RORγt (a), STAT3 (b) and SOCS3 (c) were determined via qRT-PCR. Results are presented as median (interquartile range); M: median; P25, P75: interquartile range. ^**p< 0.05 compared with that before treatment. A wilcoxon Signed-rank test was performed, and the statistical value was the T-value.

Discussion

Arsenicosis has emerged as a global public health concern. As a well-known environmental toxicant and a potent carcinogen, arsenic has been epidemiologically proved related to the manifestation of multisystem toxicity.^2–6 Studies have suggested that arsenic could cause abnormalities in inflammatory mechanisms and the immune system which negatively impact the body.^8,40,41 Many studies have indicated that arsenic could decrease the levels of CD3⁺, CD4⁺, and the CD4⁺/CD8⁺ ratio in humans and rats, as well as disrupt the balance of Th17 and Treg cells in PBMCs of rats.^33,42,43 However, the specific mechanisms of arsenic-induced immune system damage have not yet been fully elucidated.

Currently, there are no effective treatments of arseniasis in biological systems; treatment methods for arsenic-poisoning that are highly effective, lack side effects, and have low cost, should be developed. Some medicinal and edible plants were considered to attenuate the imbalance of pro-and anti-inflammatory processes. The modulation of inflammation using natural bioactive compounds poses an alternative to conventional therapeutic strategies for numerous diseases, including arseniasis.²⁴ RRTJ is a fruit crop rich in nutrients and contains bioactive molecules, including ascorbate, polysaccharides, polyphenols, and flavonoids,^44–48 also, it can be used as a dietary supplement. RRTJ can inhibit oxidative modification of low-density lipoprotein and macrophage growth and cellular cholesteryl ester accumulation in vitro.²⁹ Furthermore, RRTJ could effectively improve the immune function of arsenicosis patients by increasing the levels of CD3⁺, CD4⁺, and the CD4⁺/CD8⁺ ratio in serum. After RRTJ intervention, the levels of CD3⁺, CD4⁺, and the CD4⁺/CD8⁺ratio were increased by 6.58%, 5.11%, and 0.17%, respectively (all p < 0.05) than those in before intervention.³³ However, the specific mechanisms of RRTJ protection against immune system damage in arsenicosis patients remains unknown. As a traditional Chinese medicine and edible fruit and as a dietary supplement with potential immunoregulatory activities,⁴⁹ RRTJ was considered to be a healthy edible fruit to explore its protective effects and potential mechanism in arsenic-induced dysregulated inflammation response.

Metals or metalloid elements can be detected in hair samples that have been exposed to metalloid elements over the past 2∼18 months.⁵⁰ Thus, hair arsenic has been used as a biomarker for the total arsenic burden.⁵¹ Present data showed that the content of arsenic in the hair of arsenicosis patients was remarkably higher than that of the control group (Table2), which indicated that hair arsenic might be a biomarker of arsenicosis. RRTJ could decrease the accumulation of arsenic in the liver and hair of rats exposed to arsenic,³¹ while arsenicosis patients had lower levels of arsenic in hair after treatment with RRTJ (Table 4); however, the specific mechanisms need to be fully elucidated.

Increasing evidence from animal and human studies supports the role of arsenic exposure in dysregulated immune and inflammation responses.^8,40,41 The differentiation pathways and functional characteristics of T-cell subsets have been widely researched by immunologists. Th17 cells, a unique CD4⁺T-cell subset characterized by the production of IL-17.¹⁰ Over expression of pro-inflammatory mediators of IL-6 was observed in individuals exposed to arsenic.⁵² IL-6 is mainly produced in macrophages and lymphocytes, and it is a pleiotropic cytokine.⁵³ IL-6 is a key cytokine that initiates Th17 cell differentiation.⁵⁴ More importantly, IL-6 mediates chronic inflammation and generates a favorable cellular microenvironment for tumor growth.⁵⁵ RORγt is the most specific transcription factor promoting the production of Th17 cells. Current data suggested that the number of Th17 cells was higher in both PBMCs and CD4⁺T cells (Figure 2). Also, the expression of pro-inflammatory related cytokines IL-6 and IL-17 (Figures 3(a) and (b)) and Th17 cell-related transcription factor RORγt (Figure 4(a)) increased in the arsenic-poisoned population. This suggested that arsenic exposure can induce dysregulated immune and inflammation responses related to higher numbers of Th17 cells in PBMCs.

Dysregulation of immune and inflammation responses, which is a common mechanism of disease occurrence, was involved in arsenic-induced skin,⁵⁶ liver⁴³ and kidney⁴² damage; RRTJ can improve immune function in arsenic-poisoned rats and patients.^33,34 Therefore, it is necessary to study the role and possible mechanism of RRTJ in arsenic-induced Th17-related pro-inflammatory responses. Current data showed that RRTJ could decrease the number of Th17 cells in both PBMCs and CD4⁺T cells (Figure 5), as well as the expression of pro-inflammatory related cytokines IL-17 and IL-6 (Figure 6) and Th17 cells-related transcription factor RORγt (Figure 7(a)). Thus, RRTJ could decrease the higher concentration of Th17 cells and reduce the transcript level of RORγt, which is the specific transcription factor promoting Th17 cells, in the PBMCs of arsenicosis patients. Also, RRTJ could lower the levels of the inflammatory cytokines IL-17, which can effectively mediate pro-inflammatory responses that ultimately lead to inflammatory cell infiltration and tissue damage.¹² To our knowledge, RRTJ might be contributed to attenuate inflammation response related to higher levels of Th17 cells and their related cytokines caused by arsenic exposure on the body.

The serum levels of IL-6 were elevated in arsenicosis subjects. Typically, IL-6 binds to the IL-6 receptor subunit α IL-6R and the co-receptor gp130 to activate STAT3,⁵⁷ which consequently activates inflammatory cascades and oncogenic pathways.⁵⁸ STAT3 is a critical regulator of inflammation and the immune microenvironment, and its activation modulates the growth stimulation crosstalk of immune cells.⁵⁹ Nishihara M et al. showed a novel role of the IL-6/STAT3 signaling pathway in Th17 reaction and IL-17 production.¹⁹ IL-6 is a key factor inducing Th17 cell differentiation by activating STAT3 and increasing the activation of RORγt.⁵⁴ Conversely, SOCS3 plays an important role in inhibiting the Th17 response.²¹ As shown in present study data, qRT-PCR showed that the levels of STAT3 and SOCS3 transcription mRNA in the PBMCs were upregulated and downregulated with the degree of arsenicosis (Figures 4(b) and (c)). Combined with the higher expression of Th17 cells (Figure 2), RORγt and STAT3 (Figures 4(a) and (b)), lower level of SOCS3 (Figure 4(c)) and the abnormal levels of inflammatory cytokines IL-6 and IL-17 (Figure 3). Which suggested that arsenic exposure may induce inflammation processes related to higher Th17 cells in PBMCs. To our knowledge, the current data indicated that arsenic exposure might increase the levels of IL-6 and STAT3, implying that IL-6/STAT3 pathway may play an important role in the development of Th17-related pro-inflammatory response in the PBMCs of arsenicosis patients. As shown in Figures 7(b) and (c), after RRTJ treatment, the expression of SOCS3 increased while that of STAT3 was downregulated, which suggested that RRTJ-mediated protective effects may be involved in decreasing the levels of IL-6 and STAT3, increasing the level of SOCS3. Current study indicated that the self-healing ability (placebo treatment) for arsenic-induced Th17 cell-related pro-inflammatory response in the PBMCs of arsenicosis patients was poor (Figures 5, 6 and 7). RRTJ could attenuate Th17 cell-related inflammation response by decreasing the levels of IL-6 and STAT3, increasing the level of SOCS3 in peripheral blood of patients with arsenic poisoning (Figure 8); this indicates the application potential of RRTJ as a functional food or immunomodulator.

Figure 8.

Schematic diagram summarizing the possible mechanisms via which RRTJ protects against Th17-induced pro-inflammatory processes in the peripheral blood of patients with arsenic poisoning. Arsenic increases the level of Th17 cells, transcription factor RORγt, and Th17-related cytokines IL-17 and IL-6. RRTJ attenuates Th17-induced pro-inflammatory processes in the peripheral blood of patients with arsenic poisoning, which indicates that RRTJ decreased the stimulation of promotion of Th17-cell differentiation via up-regulation of the SOCS3-mediated IL-6/STAT3 pathway feedback inhibition.

Nonetheless, in our present study, we only detected transcriptional expression levels of STAT3, the STAT3 activity (the p-STAT3 level and nuclear translocation of STAT3) were not evaluated so that we could not obtain evidence about IL-6/STAT-3 pathway activation in PBMCs of arsenicosis individuals and its downregulation after RRTJ-treatment. Limited by our descriptive data, we aim to conduct more specific mechanism studies to elucidate the immune-protective effects and mechanism of RRTJ in vivo and in vitro in our follow-up study.

Conclusions

In summary, present study indicates that higher levels of Th17 cells as well as pro-inflammatory cytokines IL-17 and IL-6 in the peripheral blood of patients with arsenic poisoning are involved in the inflammation responses of arsenicosis. Possible immunomodulatory effects of RRTJ on the critical regulators, such as IL-6 and STAT3, of the Th17 cells in arsenicosis patients, which indicated that IL-6/STAT3 pathway might appear as a potential therapeutic target in arsenicosis.

Supplemental Material

Supplemental Material - Potential value and mechanism of Rosa roxburghii tratt juice on pro-inflammatory responses in peripheral blood of patients with arsenic poisoning

Supplemental Material for Potential value and mechanism of Rosa roxburghii tratt juice on pro-inflammatory responses in peripheral blood of patients with arsenic poisoning by Ling Dong, Shiqing Xia, Baofei Sun, Lu Ma, Xiong Chen, Shaofeng Wei, Zhonglan Zou and Aihua Zhang inHuman & Experimental Toxicology

Footnotes

Acknowledgements

We are very grateful to the medical professionals, who worked in the former 44th hospital of the Chinese People’s Liberation Army, for their invaluable medical guidance and assistance in the epidemiological investigation, physical examination, diagnosis and RRTJ intervention.

Author Contributions

Ling Dong: Methodology, Data Curation, Writing-Original Draft, Writing- Review & Editing. Shiqing Xia: Investigation, Methodology, Sample Determination, Data Curation, Writing-Original Draft, Writing-Review & Editing. Baofei Sun, Lu Ma, Xiong Chen, Shaofeng Wei and Zhonglan Zou: Investigation, Resources. Aihua Zhang: Conceptualization, Investigation, Resources, Methodology, Review & Editing, Validation, Supervision, Project administration, Funding acquisition. The manuscript was critically reviewed and approved by all authors.

Declaration of conflicting interests

The author(s) declared no potential conflicts of interest with respect to the research, authorship, and/or publication of this article.

Funding

This work was supported by the Natural Science Foundations of China (81430077 and U1812403).

ORCID iD

Aihua Zhang

Supplemental Material

Supplemental material for this article is available online.

References

Carlin

Naujokas

Bradham

, et al. Arsenic and environmental health: state of the science and future research opportunities. Environ Health Perspect 2016; 124: 890–899.

Wang

Zou

, et al. Human arsenic exposure and lung function impairment in coal-burning areas in Guizhou, China. Ecotoxicol Environ Saf 2020; 190: 110174.

Zeng

Zou

Wang

, et al. Association and risk of five miRNAs with arsenic-induced multiorgan damage. Sci Total Environ 2019; 680: 1–9.

Saint-Jacques

Brown

Nauta

, et al. Estimating the risk of bladder and kidney cancer from exposure to low-levels of arsenic in drinking water, Nova Scotia, Canada. Environ Int 2018; 110: 95–104.

Pichler

Grau-Perez

Tellez-Plaza

, et al. Association of arsenic exposure with cardiac geometry and left ventricular function in young adults. Circ Cardiovasc Imaging 2019; 12: e009018.

Dangleben

Skibola

Smith

. Arsenic immunotoxicity: a review. Environ Health 2013; 12: 73.

Huang

Lee

. Arsenic-induced carcinogenesis and immune dysregulation. Int J Environ Res Public Health 2019; 16(15): 2746.

Medina

Lauer

Castillo

, et al. Exposures to uranium and arsenic alter intraepithelial and innate immune cells in the small intestine of male and female mice. Toxicol Appl Pharmacol 2020; 403: 115155.

Parvez

Lauer

Factor-Litvak

, et al. Assessment of arsenic and polycyclic aromatic hydrocarbon (PAH) exposures on immune function among males in Bangladesh. PLoS One 2019; 14: e0216662.

10.

Bettelli

Oukka

Kuchroo

. T(H)-17 cells in the circle of immunity and autoimmunity. Nat Immunol 2007; 8: 345–350.

11.

Tesmer

Lundy

Sarkar

, et al. Th17 cells in human disease. Immunol Rev 2008; 223: 87–113.

12.

Kolls

Lindén

. Interleukin-17 family members and inflammation. Immunity 2004; 21: 467–476.

13.

Korn

Bettelli

Oukka

, et al. IL-17 and Th17 Cells. Annu Rev Immunol 2009; 27: 485–517.

14.

Xia

Sun

Zou

, et al. Ginkgo biloba extract attenuates the disruption of pro-and anti-inflammatory T-cell balance in peripheral blood of arsenicosis patients. Int J Biol Sci 2020; 16: 483–494.

15.

Hirano

Murakami

. COVID-19: A New Virus, but a Familiar Receptor and Cytokine Release Syndrome. Immunity 2020; 52: 731–733.

16.

Jones

Jenkins

. Recent insights into targeting the IL-6 cytokine family in inflammatory diseases and cancer. Nat Rev Immunol 2018; 18: 773–789.

17.

Rébé

Ghiringhelli

. STAT3, a master regulator of anti-tumor immune response. Cancers (Basel) 2019; 11(9): 1280.

18.

Yasukawa

Nagata

Oba

, et al. SOCS3: A novel therapeutic target for cardioprotection. JAKSTAT 2012; 1: 234–240.

19.

Nishihara

Ogura

Ueda

, et al. IL-6-gp130-STAT3 in T cells directs the development of IL-17+ Th with a minimum effect on that of Treg in the steady state. Int Immunol 2007; 19: 695–702.

20.

Zhu

, et al. Triptolide ameliorates IL-10-deficient mice colitis by mechanisms involving suppression of IL-6/STAT3 signaling pathway and down-regulation of IL-17. Mol Immunol 2010; 47: 2467–2474.

21.

Chen

Laurence

Kanno

, et al. Selective regulatory function of Socs3 in the formation of IL-17-secreting T cells. Proc Natl Acad Sci U S A 2006; 103: 8137–8142.

22.

Jahreis

Kuhn

Madaj

, et al. Mold metabolites drive rheumatoid arthritis in mice via promotion of IFN-gamma- and IL-17-producing T cells. Food Chem Toxicol 2017; 109: 405–413.

23.

Bhattacharya

Haldar

. Trichosanthes dioica root alleviates arsenic induced myocardial toxicity in rats. J Environ Pathol Toxicol Oncol 2013; 32: 251–261.

24.

Rahaman

Rahman

Mise

, et al. Environmental arsenic exposure and its contribution to human diseases, toxicity mechanism and management. Environ Pollut 2021; 289: 117940.

25.

Nan

Qin

, et al. [Chemical constituents from medical and edible plants of Rosa roxburghii]. Zhongguo Zhong Yao Za Zhi 2016; 41: 451–455.

26.

Chen

Liu

, et al. Inhibition of metastasis and invasion of ovarian cancer cells by crude polysaccharides from rosa roxburghii tratt in vitro. Asian Pac J Cancer Prev 2014; 15: 10351–10354.

27.

Zhang

Cai

, et al. Flavonoids of Rosa roxburghii Tratt act as radioprotectors. Asian Pac J Cancer Prev 2014; 15: 8171–8175.

28.

van der Westhuizen

van Rensburg

Rautenbach

, et al. In vitro antioxidant, antimutagenic and genoprotective activity of Rosa roxburghii fruit extract. Phytother Res 2008; 22: 376–383.

29.

Zhang

Liu

Qiang

, et al. Inhibitory effects of rosa roxburghii tratt juice on in vitro oxidative modification of low density lipoprotein and on the macrophage growth and cellular cholesteryl ester accumulation induced by oxidized low density lipoprotein. Clin Chim Acta 2001; 313: 37–43.

30.

Zhang

Sun

, et al. The preventive effect of Flavonoids of Rosa roxburghii Tratt on experimental diabetes mellitus. Acta Nutr Sin 2004: 474–476.

31.

Zeng

, et al. Assessing the potential value of Rosa Roxburghii Tratt in arsenic-induced liver damage based on elemental imbalance and oxidative damage. Environ Geochem Health 2021; 43: 1165–1175.

32.

Song

Shen

. Proteomic analysis of liver in diet-induced Hyperlipidemic mice under Fructus Rosa roxburghii action. J Proteomics 2021; 230: 103982.

33.

Zhang

Ren

, et al. [Regulating effects of Rosa roxburghii tratt preparation on immune function in arseniasis patients caused by coal burning]. Zhonghua Yu Fang Yi Xue Za Zhi 2013; 47: 783–787.

34.

Zhang

, et al. The intervention effects of Rosa roxburghii tratt strengthen SOD on immune damage in coal-fired arsenic poisoning rats. Chin J Pharmacol Toxicol 2014; 28: 233–237.

35.

NHSPRC (National Health Commission of the People’s Republic of China) . WS/T 211-2015 Diagnosis of endemic arsenicosis. Beijing: National Health Commission of the People’s Republic of China, 2015, pp. 1–3.

36.

Cluxton

Petrasca

Moran

, et al. Differential Regulation of Human Treg and Th17 Cells by Fatty Acid Synthesis and Glycolysis. Front Immunol 2019; 10: 115.

37.

Zhan

, et al. Specific histone modification responds to arsenic-induced oxidative stress. Toxicol Appl Pharmacol 2016; 302: 52–61.

38.

Samanta

Sharma

Roychowdhury

, et al. Arsenic and other elements in hair, nails, and skin-scales of arsenic victims in West Bengal, India. Sci Total Environ 2004; 326: 33–47.

39.

Pfaffl

. A new mathematical model for relative quantification in real-time RT-PCR. Nucleic Acids Res 2001; 29: e45.

40.

Burchiel

Lauer

Beswick

, et al. Differential susceptibility of human peripheral blood T cells to suppression by environmental levels of sodium arsenite and monomethylarsonous acid. PLoS One 2014; 9: e109192.

41.

Zeng

Luo

, et al. PKC θ-mediated Ca(2+)/NF-AT signalling pathway may be involved in T-cell immunosuppression in coal-burning arsenic-poisoned population. Environ Toxicol Pharmacol 2017; 55: 44–50.

42.

Zeng

Yao

, et al. A possible new mechanism and drug intervention for kidney damage due to arsenic poisoning in rats. Toxicol Res (Camb) 2016; 5: 511–518.

43.

Dong

Liu

Wang

, et al. Imbalanced inflammatory response in subchronic arsenic-induced liver injury and the protective effects of Ginkgo biloba extract in rats: Potential role of cytokines mediated cell-cell interactions. Environ Toxicol 2021; 36: 2073–2092.

44.

Hou

Yang

Zhao

, et al. Chemical characterization and comparison of two chestnut rose cultivars from different regions. Food Chem 2020; 323: 126806.

45.

Yoshida

Chen

Hatano

, et al. Tannins and related polyphenols of rosaceous medicinal plants. IV. Roxbins A and B from Rosa roxburghii fruits. Chem Pharm Bull (Tokyo) 1987; 35: 1817–1822.

46.

Zhou

Sun

, et al. Anti-browning effect of Rosa roxburghii on apple juice and identification of polyphenol oxidase inhibitors. Food Chem 2021; 359: 129855.

47.

Chen

Kan

. Characterization of a novel polysaccharide isolated from Rosa roxburghii Tratt fruit and assessment of its antioxidant in vitro and in vivo. Int J Biol Macromol 2018; 107: 166–174.

48.

Wang

. Analysis of total flavonoids of rosa roxburghii tratt in different regions of Guizhou. In: Studies of Trace Elements and Health. Geneva, Switzerland: WHO, 2007, pp. 22–23.

49.

Bao

. Effects of Rosa roxburghii tratt polysaccharide on anti-stress and immune function in mice. J Guangzhou Univ Chin Med 2002; 19: 141–142.

50.

Arain

Kazi

Baig

, et al. Respiratory effects in people exposed to arsenic via the drinking water and tobacco smoking in southern part of Pakistan. Sci Total Environ 2009; 407: 5524–5530.

51.

Shraim

Cui

, et al. Arsenic speciation in the urine and hair of individuals exposed to airborne arsenic through coal-burning in Guizhou, PR China. Toxicol Lett 2003; 137: 35–48.

52.

Chiou

, et al. Gene expression of inflammatory molecules in circulating lymphocytes from arsenic-exposed human subjects. Environ Health Perspect 2003; 111: 1429–1438.

53.

Kong

Zhou

, et al. Deletion of interleukin-6 in monocytes/macrophages suppresses the initiation of hepatocellular carcinoma in mice. J Exp Clin Cancer Res 2016; 35: 131.

54.

Kimura

Kishimoto

. IL-6: regulator of Treg/Th17 balance. Eur J Immunol 2010; 40: 1830–1835.

55.

ShengT Wang

Wang

, et al. The relationship between serum interleukin-6 and the recurrence of hepatitis B virus related hepatocellular carcinoma after curative resection. Medicine (Baltimore) 2015; 94: e941.

56.

Zeng

Zhang

. Assessing potential mechanisms of arsenic-induced skin lesions and cancers: Human and in vitro evidence. Environ Pollut 2020; 260: 113919.

57.

Tadokoro

Wang

Barak

, et al. IL-6/STAT3 promotes regeneration of airway ciliated cells from basal stem cells. Proc Natl Acad Sci U S A 2014; 111: E3641–E3649.

58.

Lee

Kim

Yang

, et al. A high-affinity protein binder that blocks the IL-6/STAT3 signaling pathway effectively suppresses non-small cell lung cancer. Mol Ther 2014; 22: 1254–1265.

59.

Jiang

Tan

Deng

, et al. Interleukin-22 promotes human hepatocellular carcinoma by activation of STAT3. Hepatology 2011; 54: 900–909.

Supplementary Material

Please find the following supplemental material available below.

For Open Access articles published under a Creative Commons License, all supplemental material carries the same license as the article it is associated with.

For non-Open Access articles published, all supplemental material carries a non-exclusive license, and permission requests for re-use of supplemental material or any part of supplemental material shall be sent directly to the copyright owner as specified in the copyright notice associated with the article.

0.00 MB

0.11 MB